Pharmaceuticals News and Research

RSS

Elderly people in the U.S. are being inappropriately prescribed medications

In the U.S. only 15 percent of the population is aged 65 years or older, but this group account for 33 percent of prescription drug users. Elderly persons are also more likely to take several drugs concurrently, the article states.

10 Aug 2004

Effects of oxidative stress on atherosclerosis

Heart disease and stroke are the first and third leading causes of death among men and women in the United States and account for 40 percent of all mortalities, according to the Centers for Disease Control and Prevention.

9 Aug 2004

Promising families of drugs combat the spread of tumors in different ways

Pharmaceutical companies seeking to design more effective cancer chemotherapy agents may have an easier road ahead than was previously believed.

9 Aug 2004

Total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010

Poised on the brink of phenomenal growth, the oligonucleotides market offers a plethora of opportunities to the enterprising investor. Recent analysis by Frost & Sullivan estimates that the total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010.

9 Aug 2004

Promising new cancer drug, Nanotax

A Lawrence company that uses patented technology created at the University of Kansas to improve the effectiveness of drugs has won a $100,000 National Institutes of Health grant to support further testing of the company's promising new cancer drug, Nanotax.

5 Aug 2004

Mayo Clinic and IBM have announced a broad collaboration to accelerate advances in patient care and research

Mayo Clinic and IBM have announced a broad collaboration to accelerate advances in patient care and research with an aggressive set of technology initiatives. The goal is to take advantage of an explosion in new medical data to drive tighter linkage between research and the practice of medicine to achieve breakthroughs.

5 Aug 2004

New gene-silencing technique

A new gene-silencing technique that takes place in the nucleus of human cells, has been demonstrated by researchers at the University of California, San Diego (UCSD) School of Medicine and the VA San Diego Healthcare System.

5 Aug 2004

Growing crisis of antibiotic-resistant bacteria

Scientists, the federal government and the pharmaceutical industry must work together quickly to solve the growing crisis of antibiotic-resistant bacteria, a Virginia Commonwealth University infectious disease expert said in today's issue of The New England Journal of Medicine.

5 Aug 2004

Nogo protein may control the progression of Alzheimer’s disease

Researchers in the Department of Neurosciences at The Cleveland Clinic Lerner Research Institute have found that Nogo, a protein known for its ability to regulate nerve regeneration, may control the progression of Alzheimer’s disease.

3 Aug 2004

Researchers study whether people’s genetic makeup could make them more likely to develop osteoarthritis of the knee and hip

Researchers at The University of Nottingham are studying whether people’s genetic makeup could make them more likely to develop osteoarthritis of the knee and hip — the most common medical condition to affect the joints.

3 Aug 2004

Michigan settlement with pharmaceutical manufacturer Schering Plough

Michigan Attorney General Mike Cox announced today a settlement with pharmaceutical manufacturer Schering Plough over its underpayment of Medicaid Drug Rebates on the antihistamine drug Claritin, netting more than $2.6 million for Michigan’s Medicaid program.

3 Aug 2004

Clinical trial established that two drugs, levodopa and pramipexole, are both viable initial treatments for Parkinson's disease

The four-year clinical trial established that two drugs, levodopa and pramipexole, are both viable initial treatments for Parkinson's disease, a degenerative disorder of the central nervous system.

3 Aug 2004

Entirely new approach to the treatment of aging

Dispelling the belief that the only way to treat such conditions is by fixing or replacing damaged genes, they instead focused on the field of epigenetics—the study of changes in gene silencing that occur without changes in the genes themselves.

3 Aug 2004

The NHS is effectively being privatised

The NHS is effectively being privatised – broken up into hundreds of competing companies with an independent regulator overseeing the system according to Professor Allyson Pollock of UCL's School of Public Policy.

3 Aug 2004

FDA approval for mint flavor nicotine gum

Watson Pharmaceuticals announced today that it has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application for nicotine polacrilex gum, mint flavor, in the 2 and 4 mg strengths.

3 Aug 2004

Metabasis Therapeutics announces multi-center Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate

Metabasis Therapeutics has announced the initiation of a multi-center, multi- national Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate in chronic hepatitis B (HBV) infected patients.

3 Aug 2004

New Drug Application with the U.S. Food and Drug Administration for Tarceva

OSI Pharmaceuticals and Genentech have announced that OSI completed the submission of a New Drug Application with the U.S. Food and Drug Administration for Tarceva (erlotinib HCl),

3 Aug 2004

New screening technique to look for genes that change patients' responses to cancer drugs and other medications

Scientists have developed a new screening technique to help them look for genes that change patients' responses to cancer drugs and other medications.

3 Aug 2004

Study evaluated the ability of vitamin E and Aricept, to delay the progression of mild cognitive impairment to Alzheimer's disease

Researchers in the neurology department in the University of Arizona College of Medicine in Tucson participated in a study that evaluated the ability of vitamin E and donepezil hydrochloride, marketed as Aricept, to delay the progression of mild cognitive impairment to Alzheimer's disease.

2 Aug 2004

Schering-Ploug will return more than $9 million to the Texas Medicaid program for the company’s fraudulent reporting of prices for drug Claritin

Texas Attorney General Greg Abbott has announced a settlement among Texas and other states with pharmaceutical giant Schering-Plough Inc. that will return more than $9 million to the Texas Medicaid program for the company’s fraudulent reporting of prices for the antihistamine drug Claritin.

2 Aug 2004

Pharmaceuticals News and Research

Elderly people in the U.S. are being inappropriately prescribed medications

Effects of oxidative stress on atherosclerosis

Promising families of drugs combat the spread of tumors in different ways

Total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010

Promising new cancer drug, Nanotax

Mayo Clinic and IBM have announced a broad collaboration to accelerate advances in patient care and research

New gene-silencing technique

Growing crisis of antibiotic-resistant bacteria

Nogo protein may control the progression of Alzheimer’s disease

Researchers study whether people’s genetic makeup could make them more likely to develop osteoarthritis of the knee and hip

Michigan settlement with pharmaceutical manufacturer Schering Plough

Clinical trial established that two drugs, levodopa and pramipexole, are both viable initial treatments for Parkinson's disease

Entirely new approach to the treatment of aging

The NHS is effectively being privatised

FDA approval for mint flavor nicotine gum

Metabasis Therapeutics announces multi-center Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate

New Drug Application with the U.S. Food and Drug Administration for Tarceva

New screening technique to look for genes that change patients' responses to cancer drugs and other medications

Study evaluated the ability of vitamin E and Aricept, to delay the progression of mild cognitive impairment to Alzheimer's disease

Schering-Ploug will return more than $9 million to the Texas Medicaid program for the company’s fraudulent reporting of prices for drug Claritin

Pittcon Highlights: Pharmaceutical & Biologic eBook

Decoding Cannabis: Differentiating Hemp and Marijuana

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Latest Life Science News